Magazine article Drug Topics

Teva Pharmaceuticals: Making Quality Healthcare Accessible

Magazine article Drug Topics

Teva Pharmaceuticals: Making Quality Healthcare Accessible

Article excerpt

Teva Pharmaceuticals is the leading generic drug company in the United States. Teva now represents 21% of the U.S. generic prescriptions, with 1 out of every 6 U.S. prescriptions being filled with a Teva product. Teva introduced 18 generic products in 2010, and had 188 Abbreviated New Drug Applications (ANDAs) pending FDA approval as of June 20, 2011. The company markets the broadest product line in the country, with nearly 400 generic products in over 1,200 dosage strengths and packaging sizes, covering all major therapeutic categories.

The Global Leader

Teva's parent company, Teva Pharmaceutical Industries Ltd., is the leading generic drug company in the world in both total and new prescriptions. The company's global presence covers North America, Europe, Latin America, Asia, and Israel. Approximately 60% of its sales is generated in North America. Teva now has approximately 40,000 employees, including nearly 6,000 within the United States, and annual net sales that totaled $16.1 billion in 2010. Teva operates in approximately 60 countries, including 40 finished dosage pharmaceutical manufacturing sites, 28 pharmaceutical research and development (R&D) centers, and 21 active pharmaceutical ingrethent (API) manufacturing sites around the world, with all pharmaceutical production facilities maintaining a uniform quality standard.

Diversified and Vertically Integrated

In addition to its leadership in the generics market, Teva has a significant and growing branded pharmaceutical portfolio, including COPAXONE® for multiple sclerosis, AZILECT® for Parkinson's disease, ProAir® for respiratory disorders, and a sizeable women's health portfolio. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.